中药治疗支气管哮喘慢性持续期的用药规律及作用机制  

The Dosing Pattern and Mechanism of Action of Chinese Medicine in the Treatment of Bronchial Asthma in the Chronic Persistent Stage

作　　者：龚春霞 潘凌宇[1] 孙叶红 韩燕全[1] 汪电雷 汪永忠[1] Gong Chunxia;Pan Lingyu;Sun Yehong;Han Yanquan;Wang Dianlei;Wang Yongzhong(The First Hospital Affiliated to Anhui University of Chinese Medicine,The Third Level Laboratory of Traditional Chinese Medicine Preparations of State Administration of Chinese Medicine,Anhui Engineering Technology Center of Modern Pharmaceutical Preparations,Anhui Key Laboratory of Chinese Herbal Compound,Hefei 230011,China;College of Pharmacy,Anhui University of Chinese Medicine,Hefei 230031,China)

机构地区：[1]安徽中医药大学第一附属医院/国家中医药管理局中药制剂三级实验室/中药复方安徽省重点实验室/现代药物制剂安徽省工程技术中心,安徽合肥230011 [2]安徽中医药大学药学院,安徽合肥230031

出　　处：《亚太传统医药》2024年第6期174-180,共7页Asia-Pacific Traditional Medicine

基　　金：安徽省高等学校自然科学研究项目(KJ2019A0440;KJ2020A0409)。

摘　　要：目的:基于数据挖掘探讨中药治疗支气管哮喘慢性持续期的用药规律,借助网络药理学技术探究核心药对治疗疾病的作用机制。方法:检索2010年1月-2023年1月中国知网、万方和维普数据库,收集文献中运用中医药为主治疗支气管哮喘慢性持续期有效的方剂,采用频次统计、关联规则分析用药规律及核心药对。利用网络药理学探索核心药对的作用机制,并使用分子对接进行验证。结果:筛选出治疗支气管哮喘慢性持续期的处方61首,中药133味。关联规则分析出三项关联规则20条,置信度和支持度最高的药对为黄芪-白术-陈皮,确定其主要活性成分为山柰酚、槲皮素、7-O-methylisomucronulatol、柚皮素和芒柄花黄素,核心靶点有鹅丝氨酸/苏氨酸蛋白激酶(AKT)1、肿瘤坏死因子(TNF)、白介素(IL)-6、肿瘤蛋白p53(TP53)和IL-1β,主要作用于PI3K-AKT信号通路、MAPK信号通路、TNF信号通路和IL-17信号通路。结论:中药治疗支气管哮喘慢性持续期的核心药对组合可通过多成分、多靶点、多通路发挥治疗作用,为临床用药提供理论依据。Objective:Based on data mining to explore the dosing pattern of Chinese medicine for the treatment of chronic persistent bronchial asthma,and with the help of network pharmacology technology to explore the mechanism of action of the core medicines for the treatment of the disease.Methods:Searching CNKI,WanFang and VIP databases from January 2010 to January 2023 to collect effective prescriptions in the literature using Chinese medicine as the main treatment for chronic persistent bronchial asthma,and analyze the pattern of medication and the core drug pairs using frequency statistics and association rules.The mechanism of action of the core drug pairs was explored using network pharmacology and validated using molecular docking.Results:Sixty-one prescriptions with 133 herbal medicines were screened for the treatment of bronchial asthma in chronic persistent phase.Three association rules were analyzed and 20 association rules were identified,and the drug pair with the highest confidence and support was Huangqi-Baizhu-Chenpi,whose main active ingredients were identified as kaempferol,quercetin,7-O-methylisomucronulatol,naringenin and formononetin,and whose core targets were goose serine/threonine kinase(AKT) 1,tumor necrosis factor(TNF),and interleukin(IL)-6,tumor protein p53(TP53) and IL-1β,mainly acting on PI3K-AKT signaling pathway,MAPK signaling pathway,TNF signaling pathway and IL-17 signaling pathway.Conclusion:The combination of core drug pairs in the treatment of chronic persistent bronchial asthma with Chinese medicine can exert therapeutic effects through multi-component,multi-target and multi-pathway,which provides theoretical basis for clinical use.

关 键 词：支气管哮喘 慢性持续期 中药 数据挖掘 网络药理学 分子对接 

分 类 号：R256.12[医药卫生—中医内科学]